Search

Your search keyword '"Kuča, Kamil"' showing total 408 results
Start Over "Kuča, Kamil" Search Limiters Available in Library Collection
408 results on '"Kuča, Kamil"'

18. Frentizole derivatives with mTOR inhibiting and senomorphic properties

Author

Chrienova, Zofia, Rysanek, David, Novak, Josef, Vasicova, Pavla, Oleksak, Patrik, Andrys, Rudolf, Skarka, Adam, Dumanovic, Jelena, Milovanovic, Zoran, Jacevic, Vesna, Chvojkova, Marketa, Holubova, Kristina, Vales, Karel, Skoupilova, Veronika, Valko, Marian, Jomova, Klaudia, Alomar, Suliman Y., Botelho, Fernanda D., Franca, Tanos C.C., Kuca, Kamil, Hodny, Zdenek, and Nepovimova, Eugenie

Published
2023
Full Text
View/download PDF

35. Leprosy: Comprehensive insights into pathology, immunology, and cutting-edge treatment strategies, integrating nanoparticles and ethnomedicinal plants.

Author

Kimta, Neetika, Majdalawieh, Amin F., Nasrallah, Gheyath K., Puri, Sunil, Nepovimova, Eugenie, Jomova, Klaudia, and Kuča, Kamil

Subjects
HANSEN'S disease, TARGETED drug delivery, MYCOBACTERIUM leprae, DRUG delivery systems, PATHOLOGY
Abstract

Mycobacterium leprae is the causative agent responsible for the chronic disease known as leprosy. This condition is characterized by dermal involvement, often leading to peripheral nerve damage, sensory-motor loss, and related abnormalities. Both innate and acquired immunological responses play a role in the disease, and even in individuals with lepromatous leprosy, there can be a transient increase in T cell immunity during lepromatous reactions. Diagnosing of early-stage leprosy poses significant challenges. In this context, nanoparticles have emerged as a promising avenue for addressing various crucial issues related to leprosy. These include combatting drug resistance, mitigating adverse effects of conventional medications, and enhancing targeted drug delivery. This review serves as a comprehensive compilation, encompassing aspects of pathology, immunology, and adverse effects of multidrug delivery systems in the context of leprosy treatment. Furthermore, the review underscores the significance of ethnomedicinal plants, bioactive secondary metabolites, and nanotherapeutics in the management of leprosy. It emphasizes the potential to bridge the gap between existing literature and ongoing research efforts, with a profound scope for validating traditional claims, developing herbal medicines, and formulating nanoscale drug delivery systems that are safe, effective, and widely accepted. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. AP-1 and SP1 trans-activate the expression of hepatic CYP1A1 and CYP2A6 in the bioactivation of AFB1 in chicken.

Author

Deng, Jiang, Yang, Jia-Cheng, Feng, Yue, Xu, Ze-Jing, Kuča, Kamil, Liu, Meng, and Sun, Lv-Hui

Abstract

Dietary exposure to aflatoxin B1 (AFB1) is harmful to the health and performance of domestic animals. The hepatic cytochrome P450s (CYPs), CYP1A1 and CYP2A6, are the primary enzymes responsible for the bioactivation of AFB1 to the highly toxic exo-AFB1-8,9-epoxide (AFBO) in chicks. However, the transcriptional regulation mechanism of these CYP genes in the liver of chicks in AFB1 metabolism remains unknown. Dual-luciferase reporter assay, bioinformatics and site-directed mutation results indicated that specificity protein 1 (SP1) and activator protein-1 (AP-1) motifs were located in the core region −1,063/−948, −606/−541 of the CYP1A1 promoter as well as −636/−595, −503/−462, −147/−1 of the CYP2A6 promoter. Furthermore, overexpression and decoy oligodeoxynucleotide technologies demonstrated that SP1 and AP-1 were pivotal transcriptional activators regulating the promoter activity of CYP1A1 and CYP2A6. Moreover, bioactivation of AFB1 to AFBO could be increased by upregulation of CYP1A1 and CYP2A6 expression, which was trans-activated owing to the upregulalion of AP-1, rather than SP1, stimulated by AFB1-induced reactive oxygen species. Additionally, nano-selenium could reduce ROS, downregulate AP-1 expression and then decrease the expression of CYP1A1 and CYP2A6, thus alleviating the toxicity of AFB1. In conclusion, AP-1 and SP1 played important roles in the transactivation of CYP1A1 and CYP2A6 expression and further bioactivated AFB1 to AFBO in chicken liver, which could provide novel targets for the remediation of aflatoxicosis in chicks. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Tacrine – Benzothiazoles: Novel class of potential multitarget anti-Alzheimeŕs drugs dealing with cholinergic, amyloid and mitochondrial systems

Author

Nepovimova, Eugenie, Svobodova, Lucie, Dolezal, Rafael, Hepnarova, Vendula, Junova, Lucie, Jun, Daniel, Korabecny, Jan, Kucera, Tomas, Gazova, Zuzana, Motykova, Katarina, Kubackova, Jana, Bednarikova, Zuzana, Janockova, Jana, Jesus, Catarina, Cortes, Luisa, Pina, Joao, Rostohar, Danijela, Serpa, Carlos, Soukup, Ondrej, Aitken, Laura, Hughes, Rebecca E., Musilek, Kamil, Muckova, Lubica, Jost, Petr, Chvojkova, Marketa, Vales, Karel, Valis, Martin, Chrienova, Zofia, Chalupova, Katarina, and Kuca, Kamil

Published
2021
Full Text
View/download PDF

41. AP-1 and SP1 trans-activate the expression of hepatic CYP1A1 and CYP2A6 in the bioactivation of AFB1in chicken

Author

Deng, Jiang, Yang, Jia-Cheng, Feng, Yue, Xu, Ze-Jing, Kuča, Kamil, Liu, Meng, and Sun, Lv-Hui

Abstract

Dietary exposure to aflatoxin B1(AFB1) is harmful to the health and performance of domestic animals. The hepatic cytochrome P450s (CYPs), CYP1A1 and CYP2A6, are the primary enzymes responsible for the bioactivation of AFB1to the highly toxic exo-AFB1-8,9-epoxide (AFBO) in chicks. However, the transcriptional regulation mechanism of these CYP genes in the liver of chicks in AFB1metabolism remains unknown. Dual-luciferase reporter assay, bioinformatics and site-directed mutation results indicated that specificity protein 1 (SP1) and activator protein-1 (AP-1) motifs were located in the core region −1,063/−948, −606/−541 of the CYP1A1promoter as well as −636/−595, −503/−462, −147/−1 of the CYP2A6promoter. Furthermore, overexpression and decoy oligodeoxynucleotide technologies demonstrated that SP1 and AP-1 were pivotal transcriptional activators regulating the promoter activity of CYP1A1and CYP2A6. Moreover, bioactivation of AFB1to AFBO could be increased by upregulation of CYP1A1and CYP2A6expression, which was trans-activated owing to the upregulalion of AP-1, rather than SP1, stimulated by AFB1-induced reactive oxygen species. Additionally, nano-selenium could reduce ROS, downregulate AP-1 expression and then decrease the expression of CYP1A1and CYP2A6, thus alleviating the toxicity of AFB1. In conclusion, AP-1 and SP1 played important roles in the transactivation of CYP1A1 and CYP2A6 expression and further bioactivated AFB1to AFBO in chicken liver, which could provide novel targets for the remediation of aflatoxicosis in chicks.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results